Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study

P B Jeppesen; M Pertkiewicz; A Forbes; L Pironi; S M Gabe; F Joly; B Messing; S Loth; N N Youssef; H Heinze; P Berghöfer

doi:10.1016/j.clnu.2013.03.016

Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study

P B Jeppesen, M Pertkiewicz, A Forbes, L Pironi, S M Gabe, F Joly, B Messing, S Loth, N N Youssef, H Heinze, P Berghöfer

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

Abstract

Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.

Original language	English
Pages (from-to)	713-721
Number of pages	9
Journal	Clinical Nutrition
Volume	32
Issue number	5
DOIs	https://doi.org/10.1016/j.clnu.2013.03.016
Publication status	Published - Oct 2013

Keywords

Adult
Aged
Cost of Illness
Double-Blind Method
Drinking
Drug Resistance
Gastrointestinal Agents
Glucagon-Like Peptide 2
Humans
Injections, Subcutaneous
Intestinal Diseases
Intestine, Small
Middle Aged
Organ Dysfunction Scores
Organ Size
Parenteral Nutrition, Home
Peptides
Quality of Life
Receptors, Glucagon
Short Bowel Syndrome

Access to Document

10.1016/j.clnu.2013.03.016

Cite this

Jeppesen, P. B., Pertkiewicz, M., Forbes, A., Pironi, L., Gabe, S. M., Joly, F., Messing, B., Loth, S., Youssef, N. N., Heinze, H., & Berghöfer, P. (2013). Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study. Clinical Nutrition, 32(5), 713-721. https://doi.org/10.1016/j.clnu.2013.03.016

@article{2b8f453a597542e8b0dcb4f3a90d23cc,

title = "Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study",

abstract = "Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.",

keywords = "Adult, Aged, Cost of Illness, Double-Blind Method, Drinking, Drug Resistance, Gastrointestinal Agents, Glucagon-Like Peptide 2, Humans, Injections, Subcutaneous, Intestinal Diseases, Intestine, Small, Middle Aged, Organ Dysfunction Scores, Organ Size, Parenteral Nutrition, Home, Peptides, Quality of Life, Receptors, Glucagon, Short Bowel Syndrome",

author = "Jeppesen, {P B} and M Pertkiewicz and A Forbes and L Pironi and Gabe, {S M} and F Joly and B Messing and S Loth and Youssef, {N N} and H Heinze and P Bergh{\"o}fer",

year = "2013",

month = oct,

doi = "10.1016/j.clnu.2013.03.016",

language = "English",

volume = "32",

pages = "713--721",

journal = "Clinical Nutrition",

issn = "0261-5614",

publisher = "Churchill Livingstone",

number = "5",

}

Jeppesen, PB, Pertkiewicz, M, Forbes, A, Pironi, L, Gabe, SM, Joly, F, Messing, B, Loth, S, Youssef, NN, Heinze, H & Berghöfer, P 2013, 'Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study', Clinical Nutrition, vol. 32, no. 5, pp. 713-721. https://doi.org/10.1016/j.clnu.2013.03.016

TY - JOUR

T1 - Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study

AU - Jeppesen, P B

AU - Pertkiewicz, M

AU - Forbes, A

AU - Pironi, L

AU - Gabe, S M

AU - Joly, F

AU - Messing, B

AU - Loth, S

AU - Youssef, N N

AU - Heinze, H

AU - Berghöfer, P

PY - 2013/10

Y1 - 2013/10

N2 - Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.

AB - Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.

KW - Adult

KW - Aged

KW - Cost of Illness

KW - Double-Blind Method

KW - Drinking

KW - Drug Resistance

KW - Gastrointestinal Agents

KW - Glucagon-Like Peptide 2

KW - Humans

KW - Injections, Subcutaneous

KW - Intestinal Diseases

KW - Intestine, Small

KW - Middle Aged

KW - Organ Dysfunction Scores

KW - Organ Size

KW - Parenteral Nutrition, Home

KW - Peptides

KW - Quality of Life

KW - Receptors, Glucagon

KW - Short Bowel Syndrome

U2 - 10.1016/j.clnu.2013.03.016

DO - 10.1016/j.clnu.2013.03.016

M3 - Article

C2 - 23587733

VL - 32

SP - 713

EP - 721

JO - Clinical Nutrition

JF - Clinical Nutrition

SN - 0261-5614

IS - 5

ER -